Global Hypercholesterolemia Drug Market by Mechanism of Action (Bile Acid Sequestrants, Fibric Acid Derivatives, HMG-CoA Reductase Inhibitors), Type of Disease (Familial hypercholesterolemia (FH), Non-Familial hypercholesterolemia (FH)), Drug Class - Forecast 2024-2030- Product Image

Sale

Global Hypercholesterolemia Drug Market by Mechanism of Action (Bile Acid Sequestrants, Fibric Acid Derivatives, HMG-CoA Reductase Inhibitors), Type of Disease (Familial hypercholesterolemia (FH), Non-Familial hypercholesterolemia (FH)), Drug Class - Forecast 2024-2030

Report
197 Pages
March 2024
Region: Global
360iResearch™
ID: 5532796

UP TO €851EUR$875USD£729GBP OFF until Dec 31^st 2024

The Hypercholesterolemia Drug Market size was estimated at USD 20.25 billion in 2023, USD 21.43 billion in 2024, and is expected to grow at a CAGR of 6.32% to reach USD 31.10 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hypercholesterolemia Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hypercholesterolemia Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hypercholesterolemia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., AstraZeneca PLC, AtheroNova Inc., Aurobindo Pharma Limited, Cipla Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, Esperion Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals Inc., Mylan N.V., Novartis AG, Pfizer Inc., and Sanofi S.A.

Market Segmentation & Coverage

This research report categorizes the Hypercholesterolemia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

Mechanism of Action
- Bile Acid Sequestrants
- Fibric Acid Derivatives
- HMG-CoA Reductase Inhibitors
- Nicotinic Acid
Type of Disease
- Familial hypercholesterolemia (FH)
- Non-Familial hypercholesterolemia (FH)
Drug Class
- Non-Statins
- Statins

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Hypercholesterolemia Drug Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hypercholesterolemia Drug Market?
What are the technology trends and regulatory frameworks in the Hypercholesterolemia Drug Market?
What is the market share of the leading vendors in the Hypercholesterolemia Drug Market?
Which modes and strategic moves are suitable for entering the Hypercholesterolemia Drug Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Hypercholesterolemia Drug Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of heart disorders worldwide
5.1.1.2. Rising unhealthy food habits coupled with increasing consumption of convenience and processed food
5.1.1.3. Increasing consumer healthcare spending and infrastructure spending by private and public organizations
5.1.2. Restraints
5.1.2.1. Availability of alternative substitutes in the market
5.1.2.2. Consumer awareness on healthy and fit diet
5.1.3. Opportunities
5.1.3.1. Technological advancements in introduction of novel drugs
5.1.3.2. Rising utilization of combination therapies across regions
5.1.4. Challenges
5.1.4.1. Competition from generic versions of branded drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Hypercholesterolemia Drug Market, by Mechanism of Action

6.1. Introduction
6.2. Bile Acid Sequestrants
6.3. Fibric Acid Derivatives
6.4. HMG-CoA Reductase Inhibitors
6.5. Nicotinic Acid

7. Hypercholesterolemia Drug Market, by Type of Disease

7.1. Introduction
7.2. Familial hypercholesterolemia (FH)
7.3. Non-Familial hypercholesterolemia (FH)

8. Hypercholesterolemia Drug Market, by Drug Class

8.1. Introduction
8.2. Non-Statins
8.3. Statins

9. Americas Hypercholesterolemia Drug Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Hypercholesterolemia Drug Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Hypercholesterolemia Drug Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Abbvie Inc.
13.1.2. Alnylam Pharmaceuticals Inc.
13.1.3. Amgen Inc.
13.1.4. AstraZeneca PLC
13.1.5. AtheroNova Inc.
13.1.6. Aurobindo Pharma Limited
13.1.7. Cipla Limited
13.1.8. Daiichi Sankyo Company, Limited
13.1.9. Dr. Reddy's Laboratories Ltd
13.1.10. Eli Lilly and Company
13.1.11. Esperion Therapeutics, Inc.
13.1.12. GlaxoSmithKline PLC
13.1.13. Ionis Pharmaceuticals Inc.
13.1.14. Mylan N.V.
13.1.15. Novartis AG
13.1.16. Pfizer Inc.
13.1.17. Sanofi S.A.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH PROCESS
FIGURE 2. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HYPERCHOLESTEROLEMIA DRUG MARKET DYNAMICS
FIGURE 7. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 8. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2030 (%)
FIGURE 10. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 12. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. HYPERCHOLESTEROLEMIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. HYPERCHOLESTEROLEMIA DRUG MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. HYPERCHOLESTEROLEMIA DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 6. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY FIBRIC ACID DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NICOTINIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 11. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA (FH), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NON-FAMILIAL HYPERCHOLESTEROLEMIA (FH), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NON-STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 27. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 28. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 30. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 31. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 45. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 47. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 48. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 53. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 54. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 71. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 72. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 82. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 84. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 85. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 88. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 90. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 91. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 100. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 109. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 112. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 114. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 115. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 126. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 136. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. HYPERCHOLESTEROLEMIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 144. HYPERCHOLESTEROLEMIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
TABLE 145. HYPERCHOLESTEROLEMIA DRUG MARKET LICENSE & PRICING

Companies Mentioned

Abbvie Inc.
Alnylam Pharmaceuticals Inc.
Amgen Inc.
AstraZeneca PLC
AtheroNova Inc.
Aurobindo Pharma Limited
Cipla Limited
Daiichi Sankyo Company, Limited
Dr. Reddy's Laboratories Ltd
Eli Lilly and Company
Esperion Therapeutics, Inc.
GlaxoSmithKline PLC
Ionis Pharmaceuticals Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sanofi S.A.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 21.43 Billion
Forecasted Market Value ( USD ) by 2030	$ 31.1 Billion
Compound Annual Growth Rate	6.3%
Regions Covered	Global
No. of Companies Mentioned	17

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3283EUR$3,374USD£2,812GBP €3648EUR$3,749USD£3,125GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4159EUR$4,274USD£3,562GBP €4621EUR$4,749USD£3,958GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5034EUR$5,174USD£4,313GBP €5594EUR$5,749USD£4,792GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5910EUR$6,074USD£5,063GBP €6567EUR$6,749USD£5,625GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7661EUR$7,874USD£6,563GBP €8513EUR$8,749USD£7,292GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Hypercholesterolemia Drug Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Homozygous Familial Hypercholesterolemia Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F

Hypercholesterolemia Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

Heterozygous Familial Hypercholesterolemia Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Market Participants, Regions, Technology, Application, Product Type

Homozygous Familial Hypercholesterolemia - Epidemiology Forecast - 2032

About the Hypercholesterolemia Drug Market